US Pharma MarketingExclusive: Treasury is assessing options to screen investments in China biotech
Treasury weighs adding biotech to outbound investment screening rules, a move that could chill or block US deals with China biotechs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
Officials at the Treasury Department are looking at potential restrictions on US investments in China biotech, according to multiple sources familiar with the discussions.
At least two sources told Endpoints News, based on direct conversations ...
Source: Endpoints News